January 17, 2024
The University of Cincinnati Cancer Center’s Maria Czyzyk-Krzeska, MD, PhD, has been awarded a five-year, $2.8 million grant from the National Institutes of Health to investigate how copper contributes to the advancement and recurrence of clear cell renal cell carcinoma.
January 12, 2024
University of Cincinnati research on how eating strawberries can reduce dementia risk was featured in a "LIVE with Kelly and Mark" segment on superfoods to eat in 2024.
January 11, 2024
WVXU highlighted a new trial at the University of Cincinnati that will test an at-home tongue endurance exercise to improve patients’ swallowing function after a stroke.
January 9, 2024
A new trial at the University of Cincinnati Gardner Neuroscience Institute, funded by a $660,000 National Institutes of Health (NIH) grant, will test an at-home tongue endurance exercise to improve patients’ swallowing function after a stroke.
January 3, 2024
The Cincinnati Enquirer reported on new harm reduction vending machines operated by Hamilton County Public Health, citing University of Cincinnati research that the vending machines increase accessibility to harm reduction products and services.
December 21, 2023
U.S. News & World Report highlighted research led by the University of Cincinnati's Francisco Romo-Nava that found spinal cord stimulation was well tolerated and has therapeutic potential to treat depression.
December 20, 2023
The University of Cincinnati's Francisco Romo-Nava published research in the journal Molecular Psychiatry that found noninvasive spinal cord stimulation is safe and has therapeutic potential to treat depression.
December 8, 2023
The University of Cincinnati's Pooja Khatri and Eva Mistry spoke with Local 12 about the SISTER trial that will test a new drug to treat patients with strokes who are not eligible to receive traditional treatments due to timing factors or risk of complications.
December 8, 2023
University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Hematology Annual Meeting, held Dec. 9-12 in San Diego, California.
December 7, 2023
The UC Gardner Neuroscience Institute has received $19 million in federal funding from the National Institutes of Health to serve as the lead center for a Phase 2 clinical trial that will study the efficacy of a new monoclonal antibody treatment for patients ineligible for currently available treatments.